HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples

Virus Research

Volumn 130, Issue 1-2, 2007, Pages 34-42

  Saracino, A ^a   Monno, L ^b   Punzi, G ^b   Cibelli, D C ^a   Tartaglia, A ^a   Scudeller, L ^c   Brindicci, G ^b   Lagioia, A ^b   Scotto, G ^a   Angarano, G ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

Biological phenotype; Coreceptor usage; env V3 loop; HIV 1

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 100; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; RNA SEQUENCE; VIRUS ENVELOPE; VIRUS ISOLATION;

CD4 LYMPHOCYTE COUNT; GIANT CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35748940958     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.05.011     Document Type: Article

References (34)

1. Alkhatib G., Combadiere C., Broder C.C., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
2. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
3. Brumme Z.L., Dong W.W., Yip B., et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 18 (2004) F1-F9
4. Clerici M., Butto S., Lukwiya M., et al. Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 29 14 (2000) 2083-2092
5. Connor R.I., and Ho D.D. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J. Virol. 68 (1994) 4400-4408
6. de Jong J.J., de Ronde A., Keulen W., et al. Syncitium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncitium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66 (1992) 6777-6780
7. de Roda Husman A.M., Koot M., and Cornelissen M. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann. Intern. Med. 127 (1997) 882-890
8. Delforge M.L., Liesnard C., Debaisieux L., et al. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 9 1 (1995) 89-90
9. Delobel P., Sandres-Sauné K., Cazabat M., et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J. AIDS 38 4 (2005) 382-392
10. Deng H., Liu R., Ellmeier W., et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
11. Dragic T., Litwin V., Allaway G.P., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996) 667-673
12. Ercoli L., Sarmati L., Nicastri E., et al. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS 11 10 (1997) 1211-1217
13. Fenyo E.M., Morfeldt-Manson L., Chiodi F., et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J. Virol. 62 (1988) 4414-4419
14. Fouchier R.A., Brouwer M., Broersen S.M., and Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncitium inducing V3 genotype by PCR. J. Clin. Microbiol. 33 (1995) 906-911
15. Furrer H., Wendland T., Minder C., et al. Association of syncitium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. AIDS 12 (1998) 1341-1346
16. Glushakova S., Yi Y., Grivel J.C., et al. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J. Clin. Invest. 104 (1999) R7-R11
17. Hill M., Lorenzo E., and Kumar A. Changes in the human immunodeficiency virus V3 region that correspond with disease progression: a meta-analysis. Virus Res. 106 (2004) 27-33
18. Holtkamp N., Otteken A., Findhammer S., et al. Unexpected coreceptor usage of primary HIV-1 isolates from viremic patients under HAART. JID 181 (2000) 513-521
19. Jensen M.A., Li F.S., van't Wout A.B., et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77 24 (2003) 13376-13388
20. Jensen M.A., and van't Wout A.B. Predicting HIV-1 coreceptor usage with sequence analiysis. AIDS Rev. 5 2 (2003) 104-112
21. Karlsson A., Parsmyr K., Sandstrom E., Fenyo E.M., and Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J. Clin. Microbiol. 32 (1994) 364-370
22. Karlsson I., Antonsson L., Shi Y., et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 5 (2003) 2561-2569
23. Maas J.J., Gange S.J., Schuitemaker H., Coutinho R.A., van Leeuwen R., and Margolick J.B. Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 14 (2000) 1155-1161
24. Moore J.P., Kitchen S.G., Pugach P., and Zack J.A. The CCR5and CXCR4 coreceptors - Central to understanding the transmission and pathogenesis of HIV-1 infection. AIDS Res. Hum. Retrov. 20 (2004) 111-126
25. Penn M., Grivel J., Schramm B., and Goldsmith M. CXCR4 utilization is sufficient to trigger CD4 + T cell depletion in HIV-1-infected human lymphoid tissue. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 663-668
26. Philpott S., Weiser B., Anastos K., et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J. Clin. Invest. 107 (2001) 431-438
27. Richman D.D., and Bozzette S.A. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169 (1994) 968-974
28. Schuitemaker H., Koot M., Kootstra N.A., et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66 (1992) 1354-1360
29. Schuitemaker H., Kootstra N.A., de Goede R.E., de Wolf F., Miedema F., and Tersmette M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 65 (1991) 356-363
30. Singh A., and Collman R.G. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies. J. Virol. 74 (2000) 10229-10235
31. Skarabal K., Trouplin V., Labrosse B., et al. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 17 (2003) 809-814
32. Tscherning C., Alaeus A., Fredriksson R., Bjorndal A., Deng H., Littman D.R., Fenyo E.M., and Albert J. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241 (1998) 181-188
33. Veazey R.S., Marx P.A., and Lackner A.A. The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol. 22 (2001) 626-633
34. Vitone F., Gibellini D., Schiavone P., and Re M.C. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. J. Clin. Virol. 33 3 (2005) 194-200 Epub 2004 Dec 15